INTRODUCTION: It is now believed that the oxidative modification of plasma lipoproteins enhance their atherogenicity in patients with type 2 diabetes. Because a variety of highly reactive lipid peroxidation products can transfer from oxidized low-density lipoprotein (ox-LDL) to high-density lipoprotein -cholesterol, the authors evaluated the association between ox-LDL and lecithin-cholesterol acyltransferase (LCAT) activity, a key enzyme in reverse cholesterol transport and HDL remodeling. METHODS: A total of 45 patients with diabetes and 45 age-, sex- and body mass index-matched healthy adult volunteers were enrolled. Fasting blood samples were obtained, and plasma glucose, lipid profile, creatinine, insulin, ox-LDL and LCAT activity were measured. Homeostasis model assessment of insulin resistance was also calculated. RESULTS: Patients with diabetes, compared with healthy participants, had a significantly higher ox-LDL (17.16 ± 3.75 U/L versus 7.93 ± 1.92 U/L, P < 0.001) and lower LCAT activity (73.7 ± 9.1 μmol/L/hr versus 88.7 ± 4.5 μmol/L/hr, P < 0.001). The higher level of LCAT activity completely disappeared after adjustment for ox-LDL. LCAT activity had a significant (P < 0.001) inverse correlation with ox-LDL (r = -0.77) in patients with diabetes and healthy participants (r = -0.75). CONCLUSION: LCAT activity is significantly decreased in type 2 diabetes. The lower LCAT activity in type 2 diabetes might be through ox-LDL mechanism. Ox-LDL may adversely affect high-density lipoprotein -cholesterol metabolism by reducing LCAT activity.
INTRODUCTION: It is now believed that the oxidative modification of plasma lipoproteins enhance their atherogenicity in patients with type 2 diabetes. Because a variety of highly reactive lipid peroxidation products can transfer from oxidized low-density lipoprotein (ox-LDL) to high-density lipoprotein -cholesterol, the authors evaluated the association between ox-LDL and lecithin-cholesterol acyltransferase (LCAT) activity, a key enzyme in reverse cholesterol transport and HDL remodeling. METHODS: A total of 45 patients with diabetes and 45 age-, sex- and body mass index-matched healthy adult volunteers were enrolled. Fasting blood samples were obtained, and plasma glucose, lipid profile, creatinine, insulin, ox-LDL and LCAT activity were measured. Homeostasis model assessment of insulin resistance was also calculated. RESULTS:Patients with diabetes, compared with healthy participants, had a significantly higher ox-LDL (17.16 ± 3.75 U/L versus 7.93 ± 1.92 U/L, P < 0.001) and lower LCAT activity (73.7 ± 9.1 μmol/L/hr versus 88.7 ± 4.5 μmol/L/hr, P < 0.001). The higher level of LCAT activity completely disappeared after adjustment for ox-LDL. LCAT activity had a significant (P < 0.001) inverse correlation with ox-LDL (r = -0.77) in patients with diabetes and healthy participants (r = -0.75). CONCLUSION:LCAT activity is significantly decreased in type 2 diabetes. The lower LCAT activity in type 2 diabetes might be through ox-LDL mechanism. Ox-LDL may adversely affect high-density lipoprotein -cholesterol metabolism by reducing LCAT activity.
Authors: W Sean Davidson; Anna Heink; Hannah Sexmith; Lawrence M Dolan; Scott M Gordon; James D Otvos; John T Melchior; Deborah A Elder; Jane Khoury; Esmond Geh; Amy S Shah Journal: J Lipid Res Date: 2017-07-25 Impact factor: 5.922
Authors: Mateo Amaya-Montoya; Jairo A Pinzón-Cortés; Lina S Silva-Bermúdez; Daniel Ruiz-Manco; Maria C Pérez-Matos; Mario A Jiménez-Mora; Carlos O Mendivil Journal: Lipids Health Dis Date: 2020-05-25 Impact factor: 3.876
Authors: Gabriele Mocciaro; Simona D'Amore; Benjamin Jenkins; Richard Kay; Antonio Murgia; Luis Vicente Herrera-Marcos; Stefanie Neun; Alice P Sowton; Zoe Hall; Susana Alejandra Palma-Duran; Giuseppe Palasciano; Frank Reimann; Andrew Murray; Patrizia Suppressa; Carlo Sabbà; Antonio Moschetta; Albert Koulman; Julian L Griffin; Michele Vacca Journal: Int J Mol Sci Date: 2022-06-17 Impact factor: 6.208
Authors: Jane-Ann Daniels; Ciara Mulligan; David McCance; Jayne V Woodside; Christopher Patterson; Ian S Young; Jane McEneny Journal: Cardiovasc Diabetol Date: 2014-01-14 Impact factor: 9.951